Clinical TrialsVanda Reports Positive Results for Tradipitant in GLP-1 Vomiting Vanda Reports Positive Results for Tradipitant in GLP-1 Vomiting Read Post »
Clinical TrialsBeam’s BEAM-301 Shows Early Metabolic Benefits in GSDIa Beam’s BEAM-301 Shows Early Metabolic Benefits in GSDIa Read Post »
Clinical TrialsArtiva Ends AlloNK Development After Durability Shortfall and Two Fatal Eve... Artiva Ends AlloNK Development After Durability Shortfall and Two Fatal Eve... Read Post »
Clinical TrialsPfizer Reports Positive PFS Results for ELREXFIO in RRMM Trial Pfizer Reports Positive PFS Results for ELREXFIO in RRMM Trial Read Post »
Clinical TrialsOncolytics Reports Promising Survival Data With Pelareorep Combination Oncolytics Reports Promising Survival Data With Pelareorep Combination Read Post »
Clinical TrialsTonix Reports Positive FIQR Results for TONMYA in Fibromyalgia Trials Tonix Reports Positive FIQR Results for TONMYA in Fibromyalgia Trials Read Post »
Clinical TrialsHenlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Henlius Reports Longer Overall Survival With Serplulimab in ES-SCLC Read Post »
Clinical TrialsMerck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Merck KGaA Reports Durable Tumor Control With Pimicotinib at Two Years Read Post »
Clinical TrialsIambic’s IAM1363 Shows Early Activity Against Brain Metastases Iambic’s IAM1363 Shows Early Activity Against Brain Metastases Read Post »
Clinical TrialsIncyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Incyte Reports Strong Responses with KRAS G12D and TGFβR2×PD-1 Therapies Read Post »
Clinical TrialsMirum Reports Positive Zilurgisertib Results in Children With FOP Mirum Reports Positive Zilurgisertib Results in Children With FOP Read Post »
Clinical TrialsCorcept Reports Positive BELLA Results for Lifyorli Triplet Corcept Reports Positive BELLA Results for Lifyorli Triplet Read Post »
Clinical TrialsJ&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT J&J Reports 62% EFS Risk Reduction With ERLEADA Plus ADT Read Post »
Clinical TrialsAgenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Agenus Reports 72% Complete Response with BOT+BAL in dMMR Colon Cancer Read Post »
Clinical TrialsAstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint AstraZeneca’s Sonesitatug Vedotin Meets OS but Misses PFS Endpoint Read Post »
Clinical TrialsJ&J Reports Strong Tumour Responses With RYBREVANT FASPRO J&J Reports Strong Tumour Responses With RYBREVANT FASPRO Read Post »
Clinical TrialsParabilis Reports 100% Disease Control With Zolucatetide in Desmoid Tumors Parabilis Reports 100% Disease Control With Zolucatetide in Desmoid Tumors Read Post »
Clinical TrialsCatalYm Reports Higher Responses With Visugromab in Bladder Cancer CatalYm Reports Higher Responses With Visugromab in Bladder Cancer Read Post »
Clinical TrialsRoche’s Divarasib Improves Survival in KRAS G12C Lung Cancer Roche’s Divarasib Improves Survival in KRAS G12C Lung Cancer Read Post »
Clinical TrialsGSK’s Mo-Rez Shows 62% Response Rate in Ovarian Cancer GSK’s Mo-Rez Shows 62% Response Rate in Ovarian Cancer Read Post »
Clinical TrialsGenmab’s Rina-S Reduces Death Risk by 57% in Ovarian Cancer Trial Genmab’s Rina-S Reduces Death Risk by 57% in Ovarian Cancer Trial Read Post »
Clinical TrialsPalleon Reports Faster Responses With HLX79/E-602 in pMN Trial Palleon Reports Faster Responses With HLX79/E-602 in pMN Trial Read Post »
Clinical TrialsRemibrutinib Cuts MS Relapses by Up to 35% in Phase 3 Trials Remibrutinib Cuts MS Relapses by Up to 35% in Phase 3 Trials Read Post »
Clinical TrialsTakeda’s Arcotatug Tavatecan Deliver Dual Survival Benefits in G-HOPE-001... Takeda’s Arcotatug Tavatecan Deliver Dual Survival Benefits in G-HOPE-001... Read Post »
Clinical TrialsBMS’s Zola-cel Shows Early Promise in Relapsing and Progressive MS BMS’s Zola-cel Shows Early Promise in Relapsing and Progressive MS Read Post »
Clinical TrialsRevMed Reports RASONQUE Survival Benefit Across RAS Subgroups RevMed Reports RASONQUE Survival Benefit Across RAS Subgroups Read Post »
Clinical TrialsORIC Plans Phase 3 After Positive Enozertinib Results in NSCLC ORIC Plans Phase 3 After Positive Enozertinib Results in NSCLC Read Post »
Clinical TrialsAlnylam’s Brezosiran Delivers Up to 64% Mean Huntingtin Reduction Alnylam’s Brezosiran Delivers Up to 64% Mean Huntingtin Reduction Read Post »
Clinical TrialsEvaxion Reports Sustained EVX-01 Responses in Advanced Melanoma Evaxion Reports Sustained EVX-01 Responses in Advanced Melanoma Read Post »
Clinical TrialsMineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Mineralys Reports 52.2% Albuminuria Reduction With Lorundrostat Read Post »
Clinical TrialsVor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Vor Bio Reports Positive Two-Year TELIGAN Results in IgA Nephropathy Read Post »
Clinical TrialsAbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa AbbVie Reports Phase 3 Success for Lutikizumab in Hidradenitis Suppurativa Read Post »
Clinical TrialsOtsuka Reports 97.1% Lower Kidney Outcome Risk With VOYXACT Otsuka Reports 97.1% Lower Kidney Outcome Risk With VOYXACT Read Post »
Clinical TrialsTG Reports 7-Year BRIUMVI Outcomes and Positive ENHANCE Results TG Reports 7-Year BRIUMVI Outcomes and Positive ENHANCE Results Read Post »
Clinical TrialsShionogi Reports 76.7% Clinical Response With Cefiderocol in U.S. Cohort Shionogi Reports 76.7% Clinical Response With Cefiderocol in U.S. Cohort Read Post »
Clinical TrialsOculis Reports Reduced NfL and GFAP Rises in Phase 2 ACUITY Trial Oculis Reports Reduced NfL and GFAP Rises in Phase 2 ACUITY Trial Read Post »
Clinical TrialsSavara Reports Gas-Transfer Gains with Molgramostim in aPAP Savara Reports Gas-Transfer Gains with Molgramostim in aPAP Read Post »
Clinical TrialsTaiMed Reports Up to 1.57-Log HIV-1 RNA Reduction With TMB-365 TaiMed Reports Up to 1.57-Log HIV-1 RNA Reduction With TMB-365 Read Post »
Clinical TrialsRoche Reports Reduced Chronic Lesion Activity Across MS Trials Roche Reports Reduced Chronic Lesion Activity Across MS Trials Read Post »
Clinical TrialsRoivant Reports Positive Phase 3 Results for Brepocitinib in Uveitis Roivant Reports Positive Phase 3 Results for Brepocitinib in Uveitis Read Post »
Clinical TrialsLumen’s LMN-201 Shows Positive RePreve Results in C. difficile Lumen’s LMN-201 Shows Positive RePreve Results in C. difficile Read Post »
Clinical TrialsRapport’s RAP-219 Delivers Significant YMRS Improvement in Phase 2 Rapport’s RAP-219 Delivers Significant YMRS Improvement in Phase 2 Read Post »
Clinical TrialsAstraZeneca and Amgen Report Sustained Histologic Remission With Tezspire AstraZeneca and Amgen Report Sustained Histologic Remission With Tezspire Read Post »
Clinical TrialsTeva and Sanofi Report Sustained Week 44 Duvakitug Outcomes in IBD Teva and Sanofi Report Sustained Week 44 Duvakitug Outcomes in IBD Read Post »
Clinical TrialsJ&J Reports Long-Term Crohn’s Outcomes and Fistula Data for TREMFYA J&J Reports Long-Term Crohn’s Outcomes and Fistula Data for TREMFYA Read Post »
Clinical TrialsXBiotech’s Vilamakitug Meets TASKIN Trial’s 12-Month Survival Threshold XBiotech’s Vilamakitug Meets TASKIN Trial’s 12-Month Survival Threshold Read Post »
Clinical TrialsVeradermics Reports Higher Hair Growth With VDPHL01 in Phase 3 Veradermics Reports Higher Hair Growth With VDPHL01 in Phase 3 Read Post »
Clinical TrialsDisc’s Bitopertin Meets All Phase 3 APOLLO Endpoints in EPP Disc’s Bitopertin Meets All Phase 3 APOLLO Endpoints in EPP Read Post »
Clinical TrialsEyePoint’s DURAVYU Fails Wet AMD Trial EyePoint’s DURAVYU Fails Wet AMD Trial Read Post »
Clinical TrialsIDEAYA Reports Three-Trial Progress for Darovasertib in Uveal Melanoma IDEAYA Reports Three-Trial Progress for Darovasertib in Uveal Melanoma Read Post »